Physician profile
Terrence P Reding
NPI 1922150150
$722.65
in general payments reported to CMS, 2019-2025
15 companies · $54.18 in 2025
The $54.18 reported for 2025 was less than what a typical Sports Medicine (Internal Medicine) provider received nationally (typical 2025 total: $99.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.89 · 2020: $56.84 · 2021: $200 · 2022: $156 · 2023: $78.67 · 2024: $115 · 2025: $54.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $247.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $126.18 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $118.68 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.56 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $82.82 | 2021-2023 | Vaxelis, M-M-R II, Gardasil 9 |
| Glaxosmithkline, LLC. | $76.94 | 2019-2023 | Bexsero, Pediarix |
| Biohaven Pharmaceutical Holding Company LTD. | $30.22 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $27.51 | 2024 | |
| Gilead Sciences, INC. | $26.54 | 2019 | |
| Pfizer INC. | $24.83 | 2024 | |
| Organon LLC | $24.64 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.28 | 2022 | |
| Mannkind Corporation | $16.91 | 2023 | Afrezza |
| Alkermes, INC. | $14.74 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.43 | 2021 | |
| Verrica Pharmaceuticals INC. | $13.37 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrence Reding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.